Refine by
Molecular Pathway Articles & Analysis
23 news found
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform and ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
Cellworks Group, Inc., a world leader in Genomic Biosimulation Services for Precision Pharma and Personalized Oncology, today announced it has won The Challengers Innovative Business of the Year Award. Dell Technologies, in collaboration with Moneycontrol, CNBC TV-18, Intel, and Ernst and Young, established The Challengers Awards to recognize the agility and innovation displayed by IT innovators. ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A study, which demonstrate that the Cellworks Biosimulation Platform and SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) for non-small cell lung cancer (NSCLC) patients and can provide ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-004 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) is highly predictive of Overall Survival (OS), Disease-Free Survival (DFS) and Mandard-tumor regression grade (TRG) for gastroesophageal adenocarcinoma ...
Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to ...
“We have established an approach that transforms real-world, in-human treatment outcomes and safety data into extensive datasets to better characterize desirable and undesirable interactions between molecular pathways and drugs,” explains Dr. David Jackson, Chief Innovation Officer at Molecular Health and co-author on all three articles. “The studies demonstrate a standardized ...
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae Zetagen Therapeutics, a private, ...
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), ...
NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply ...
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-023 clinical trial, which found that the Cellworks Biosimulation Platform with its Therapy Response Index (TRI) reliably predicts complete response (CR) and overall survival (OS) for individual Acute Myeloid Leukemia (AML) patients beyond ...
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
Nuritas, a biotechnology company revolutionizing the discovery and development of plant-based bioactive peptides, has closed a $45 million USD Series B funding round. The investment, led by Chicago-based Cleveland Avenue, LLC, includes Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund (ECBF), Singapore-based Vertex Holdings, Nutresa Ventures/ Veronorte and CJ. Cultivian ...
Profacgen, a US-based biotechnology company, recognizing the importance of computational technologies for pursuing advanced research in modern biology, released custom bioinformatics software development to offer support for both academic and industrial researchers to explore, understand and analyze complex biological data in a variety of biotechnology programs and projects. Bioinformatics ...
On August 1, 2021, the IT biotech company Molecular Health (MH) and Universitätsklinikum Essen kicked off a collaborative project funded by the BMG (Bundesministerium für Gesundheit [German Federal Ministry of Health]) to provide holistic and evidence-based care for COVID-19 patients. Using the MH Corona Explorer, a deeper understanding of the disease will be generated, linking the ...
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ Company’s intellectual property pipeline targets other oncologic ...
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...